Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models

Journal of Pathology

Volumn 233, Issue 2, 2014, Pages 124-137

  Melchor, Lorenzo ^a   Molyneux, Gemma ^a,f   Mackay, Alan ^a   Magnay, Fiona Ann ^a   Atienza, María ^b   Kendrick, Howard ^a,h   Nava Rodrigues, Daniel ^a   López García, María Ángeles ^b   Milanezi, Fernanda ^a,g   Greenow, Kirsty ^c   Robertson, David ^a   Palacios, José ^d   Reis Filho, Jorge S ^e   Smalley, Matthew J ^a,h  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g Division of Immunology Infection and Inflammatory Diseases King's College London 1st Floor New Hunt's House ^*  (Brazil)

^h CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

basal like; Brca2; breast cancer molecular subtypes; p53; Pten; tumour heterogeneity

Indexed keywords

BRCA2 PROTEIN; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL CELL; BREAST CANCER; BREAST CARCINOMA; BREAST EPITHELIUM; CONTROLLED STUDY; GENE EXPRESSION; GENETICALLY ENGINEERED MOUSE STRAIN; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

BASAL-LIKE; BRCA2; BREAST CANCER MOLECULAR SUBTYPES; P53; PTEN; TUMOUR HETEROGENEITY;

ANIMALS; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLAUDINS; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAMMARY GLANDS, ANIMAL; MICE; MICE, KNOCKOUT; PHENOTYPE; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84900559085     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4345     Document Type: Article

References (34)

1. Sorlie T, Tibshirani R, Parker J, et al., Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
2. Reis-Filho JS, Pusztai L,. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011; 378: 1812-1823.
3. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
4. Lakhani SR, Ellis IO, Schnitt SJ, et al., WHO Classification of Tumors of the Breast, 4th edn. IARC Press: Lyon, France, 2012.
5. Visvader JE,. Cells of origin in cancer. Nature 2011; 469: 314-322.
6. Prat A, Perou CM,. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
7. Melchor L, Benitez J,. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. Carcinogenesis 2008; 29: 1475-1482.
8. Smalley M, Ashworth A,. Stem cells and breast cancer: a field in transit. Nat Rev Cancer 2003; 3: 832-844.
9. Foulkes WD,. BRCA1 functions as a breast stem cell regulator. J Med Genet 2004; 41: 1-5.
10. Dontu G, Al-Hajj M, Abdallah WM, et al., Stem cells in normal breast development and breast cancer. Cell Prolif 2003; 36 (suppl 1): 59-72.
11. Lim E, Vaillant F, Wu D, et al., Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-913.
12. Proia TA, Keller PJ, Gupta PB, et al., Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011; 8: 149-163.
13. Molyneux G, Geyer FC, Magnay FA, et al., BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010; 7: 403-417.
14. Robertson D, Savage K, Reis-Filho JS, et al., Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol 2008; 9: 13.
15. Maiques O, Santacana M, Valls J, et al., Optimal protocol for PTEN immunostaining: role of analytical and pre-analytical variables in PTEN staining in normal and neoplastic endometrial, breast and prostatic tissues. Human Pathology 2014; 45: 522-532.
16. Castilla MÁ, Díaz-Martín J, Sarriõ D, et al., MicroRNA-200 Family modulation in distinct breast cancer phenotypes. PLoS One 2012; 7: e47709.
17. Weigelt B, Mackay A, A'Hern R, et al., Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010; 11: 339-349.
18. Parker JS, Mullins M, Cheang MC, et al., Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
19. Berger AH, Pandolfi PP,. Haplo-insufficiency: a driving force in cancer. J Pathol 2011; 223: 137-146.
20. McCarthy A, Savage K, Gabriel A, et al., A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol 2007; 211: 389-398.
21. Hu Z, Fan C, Oh DS, et al., The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 2006; 7: 96.
22. Prat A, Parker JS, Karginova O, et al., Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
23. van de Vijver MJ, He YD, van't Veer LJ, et al., A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
24. Waddell N, Arnold J, Cocciardi S, et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat 2010; 123: 661-677.
25. Jonsson G, Staaf J, Vallon-Christersson J, et al., The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer. Cancer Res 2012; 72: 4028-4036.
26. Larsen MJ, Kruse TA, Tan Q, et al., Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One 2013; 8: e64268.
27. Peto J, Collins N, Barfoot R, et al., Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999; 91: 943-949.
28. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al., The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310-2318.
29. Palacios J, Honrado E, Osorio A, et al., Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003; 9: 3606-3614.
30. Melchor L, Benitez J,. The complex genetic landscape of familial breast cancer. Hum Genet 2013; 132: 845-863.
31. Banneau G, Guedj M, MacGrogan G, et al., Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 2010; 12: R63.
32. Derksen PW, Liu X, Saridin F, et al., Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006; 10: 437-449.
33. Liu X, Holstege H, van der Gulden H, et al., Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 2007; 104: 12111-12116.
34. Kendrick H, Regan JL, Magnay FA, et al., Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genom 2008; 9: 591.